Palatin Technologies (PTN) Other Non Operating Income (2020 - 2026)
Palatin Technologies' (PTN) quarterly Other Non Operating Income came in at $148007.0 in Q1 2026, up 630.49% YoY from $20261.3 in Q1 2025, and up 128.8% on a QoQ basis from $64687.0 in Q4 2025.
Palatin Technologies (PTN) Other Non Operating Income (2020 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 7 years of Other Non Operating Income data on file, last reported at $148007.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 630.49% year-over-year to $148007.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $397665.0 (up 105.48% YoY) and the FY2025 annual result came in at $152590.0, up 102.11% from the prior year.
- Other Non Operating Income improved to $148007.0 in Q1 2026, from $64687.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $3.6 million in Q4 2022 to a low of -$8.1 million in Q4 2023.
- A 5-year average of -$820212.9 and a median of $143600.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 1646.19% — and 2023, when it plunged 1075.38%.
- Tracing PTN's Other Non Operating Income over 5 years: stood at $3.6 million in 2022, then sank by 323.08% to -$8.1 million in 2023, then soared by 101.78% to $143600.0 in 2024, then sank by 54.95% to $64687.0 in 2025, then jumped by 128.8% to $148007.0 in 2026.
- The last three Other Non Operating Income figures came in at $148007.0 (Q1 2026), $64687.0 (Q4 2025), and $16481.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148,007.00 |
| Dec 31, 2025 | 64,687.00 |
| Sep 30, 2025 | 16,481.00 |
| Jun 30, 2025 | 168,490.00 |
| Mar 31, 2025 | -27,900.00 |
| Dec 31, 2024 | 143,600.00 |
| Sep 30, 2024 | -58,964.00 |
| Jun 30, 2024 | -7.31 Mn |
| Mar 31, 2024 | 215,600.00 |
| Dec 31, 2023 | -8.07 Mn |
| Sep 30, 2023 | 682,400.00 |
| Jun 30, 2023 | -3.18 Mn |
| Mar 31, 2023 | -1.37 Mn |
| Dec 31, 2022 | 3.62 Mn |
| Sep 30, 2022 | 497,263.00 |
| Jun 30, 2022 | 325,868.00 |
| Mar 31, 2022 | 190,719.00 |
| Dec 31, 2021 | -234,078.00 |
| Sep 30, 2021 | 107,359.00 |
| Jun 30, 2021 | -221,274.00 |